37.30
price up icon0.23%   0.03
 
loading
Royalty Pharma Plc stock is traded at $37.30, with a volume of 1.25M. It is up +0.23% in the last 24 hours and up +3.68% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$37.27
Open:
$37.1
24h Volume:
1.25M
Relative Volume:
0.33
Market Cap:
$15.72B
Revenue:
$2.26B
Net Income/Loss:
$1.09B
P/E Ratio:
15.92
EPS:
2.3431
Net Cash Flow:
$2.70B
1W Performance:
+3.74%
1M Performance:
+3.68%
6M Performance:
+18.25%
1Y Performance:
+30.89%
1-Day Range:
Value
$36.84
$37.50
1-Week Range:
Value
$36.00
$37.56
52-Week Range:
Value
$24.05
$37.56

Royalty Pharma Plc Stock (RPRX) Company Profile

Name
Name
Royalty Pharma Plc
Name
Phone
(212) 883-0200
Name
Address
110 EAST 59TH STREET, NEW YORK, NY
Name
Employee
99
Name
Twitter
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RPRX
Royalty Pharma Plc
37.30 15.62B 2.26B 1.09B 2.70B 2.3431
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.46 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.58 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
345.30 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
605.40 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.20 31.87B 3.81B -644.79M -669.77M -6.24

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-16-25 Initiated Morgan Stanley Overweight
Jun-03-24 Downgrade UBS Buy → Neutral
Jun-14-22 Resumed UBS Buy
May-13-22 Initiated Scotiabank Sector Outperform
Apr-27-22 Initiated Goldman Buy
Apr-14-22 Upgrade JP Morgan Neutral → Overweight
Apr-06-22 Resumed Morgan Stanley Overweight
Oct-29-21 Upgrade Citigroup Neutral → Buy
Jul-30-21 Initiated Tigress Financial Buy
Nov-09-20 Upgrade UBS Neutral → Buy
Jul-14-20 Initiated Evercore ISI In-line
Jul-13-20 Initiated BofA Securities Buy
Jul-13-20 Initiated Citigroup Neutral
Jul-13-20 Initiated Cowen Outperform
Jul-13-20 Initiated Goldman Neutral
Jul-13-20 Initiated JP Morgan Neutral
Jul-13-20 Initiated Morgan Stanley Equal-Weight
Jul-13-20 Initiated SunTrust Buy
Jul-13-20 Initiated UBS Neutral
View All

Royalty Pharma Plc Stock (RPRX) Latest News

pulisher
10:00 AM

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

10:00 AM
pulisher
06:30 AM

Pacific Capital Partners Ltd Takes Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

06:30 AM
pulisher
03:34 AM

Envestnet Asset Management Inc. Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

03:34 AM
pulisher
Jul 29, 2025

Royalty Pharma plc stock volume spike explainedScalable Portfolio Growth Suggestions Released - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 22:21:39 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Baillie Gifford & Co. Decreases Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 29, 2025
pulisher
Jul 29, 2025

Machine Learning Models Forecast Royalty Pharma plc UptickConsistent Income Focused Trade List Analyzed - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Can Royalty Pharma plc Regain Momentum After BreakdownCommunity Shared Smart Money Signals Show Movement - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Bollinger Bands Expand on Royalty Pharma plc — Volatility AheadWeekly Chart Analysis With Entry Advice Provided - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Royalty Pharma stock hits 52-week high at 36.89 USD - Investing.com Australia

Jul 28, 2025
pulisher
Jul 28, 2025

Why is Royalty Pharma plc stock attracting strong analyst attentionExceptional stock performance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is it the right time to buy Royalty Pharma plc stockSuperior portfolio returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Ridgewood Investments LLC Decreases Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

What makes Royalty Pharma plc stock price move sharplyInvest confidently with real-time updates - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Mediolanum International Funds Ltd Lowers Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Royalty Pharma PLC (NASDAQ:RPRX) Position Trimmed by Allianz Asset Management GmbH - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Cwm LLC Increases Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

What is Royalty Pharma plc company’s growth strategyUnmatched profit growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Royalty Pharma plc compare to its industry peersCapitalize on strong market momentum - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is Royalty Pharma plc stock overvalued or undervaluedUnlock powerful trading signals and alerts - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-28 08:51:02 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Royalty Pharma plcMaximize your portfolio’s earning potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

When is Royalty Pharma plc stock expected to show significant growthDynamic profit opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What markets is GCLWW expanding into Is Royalty Pharma plc stock a good long term investment optionGet daily updates on promising stocks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Vestor Capital LLC Takes $12.60 Million Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 27, 2025
pulisher
Jul 26, 2025

Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month HighHere's What Happened - MarketBeat

Jul 26, 2025
pulisher
Jul 26, 2025

Royalty Pharma: A High-Margin, Earnings-Driven Opportunity in the Biopharma Royalty Space - AInvest

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Royalty Pharma plc stockFree Wealth Planning Blueprint - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Royalty Pharma plc Stock Analysis and ForecastSuperior portfolio returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is Royalty Pharma plc a good long term investmentDouble-digit growth - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Royalty Pharma (NASDAQ:RPRX) Given New $42.00 Price Target at Citigroup - MarketBeat

Jul 25, 2025
pulisher
Jul 24, 2025

Royalty Pharma PLC (NASDAQ:RPRX) Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by New York State Common Retirement Fund - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Royalty Pharma Plc's (NASDAQ:RPRX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - 富途牛牛

Jul 24, 2025
pulisher
Jul 24, 2025

Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Edgestream Partners L.P. Makes New $659,000 Investment in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Royalty Pharma plc stock pricePhenomenal wealth increase - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Citigroup maintains Buy rating, raises PT for Royalty Pharma to $42. - AInvest

Jul 22, 2025

Royalty Pharma Plc Stock (RPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.85
price up icon 0.63%
$107.11
price up icon 2.25%
$27.00
price up icon 1.10%
$111.50
price up icon 0.02%
biotechnology ONC
$301.20
price down icon 1.28%
Cap:     |  Volume (24h):